New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar

As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.

👉 Click here to access your FREE report now!

Paul Szurek Biography and Net Worth

CEO of Cencora

Paul E. Szurek has served as our President and Chief Executive Officer since September 2016, and as a director since September 2010. From 2003 to August 2016, Mr. Szurek was Chief Financial Officer of Biltmore Farms, LLC, a residential and commercial real estate development and operating company. Prior to joining Biltmore Farms, LLC, Mr. Szurek served as Chief Financial Officer of Security Capital Group Incorporated, a publicly traded real estate investment, development and operating company with extensive REIT engagement. He has also previously served as a director of the Charlotte, North Carolina branch of the Federal Reserve Bank of Richmond and as a director to two publicly traded real estate companies, Regency Centers and Security Capital U.S. Realty. Mr. Szurek received a J.D. with honors from Harvard Law School and a B.A. in Government, magna cum laude, from the University of Texas at Austin.

What is Paul E. Szurek's net worth?: The estimated net worth of Paul E. Szurek is at least $2.94 million as of May 25th, 2016. Mr. Szurek owns 12,100 shares of Cencora stock worth more than $2,942,720 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Szurek may own. Learn More about Paul E. Szurek's net worth.
How do I contact Paul E. Szurek?: The corporate mailing address for Mr. Szurek and other Cencora executives is 1300 MORRIS DRIVE, CHESTERBROOK PA, 19087. Cencora can also be reached via phone at (610) 727-7000 and via email at [email protected]. Learn More on Paul E. Szurek's contact information.
Has Paul E. Szurek been buying or selling shares of Cencora?: Paul E. Szurek has not been actively trading shares of Cencora within the last three months. Learn More on Paul E. Szurek's trading history.
Who are Cencora's active insiders?: Cencora's insider roster includes Silvana Battaglia (EVP), Elizabeth Campbell (EVP), John Chou (EVP), Gina Clark (EVP), Gina Clark (EVP), Steven Collis (CEO), Leslie Donato (EVP), Leslie Donato (EVP), Jeffrey Finnin (CFO), Juan Font (SVP), Jane Henney, MD (Director), Mark Jones (CAO), Maile Kaiser (SVP), Michael Koehler (Director), Lazarus Krikorian (CAO), Aleksandra Krusko (SVP), Robert Mauch (EVP), Robert Mauch (COO), Derek McCandless (SVP), Henry McGee, III (Director), Steven Smith (CRO), Paul Szurek (CEO), and Brian Warren (SVP). Learn More on Cencora's active insiders.
Are insiders buying or selling shares of Cencora?: During the last year, Cencora insiders bought shares 1 times. They purchased a total of 500 shares worth more than $109,290.00. During the last year, insiders at the sold shares 15 times. They sold a total of 10,679,455 shares worth more than $2,497,519,666.75. The most recent insider tranaction occured on October, 22nd when Chairman Steven H Collis sold 21,509 shares worth more than $5,071,822.20. Insiders at Cencora own 15.8% of the company. Learn More about insider trades at Cencora.
Information on this page was last updated on 10/22/2024.

Paul E. Szurek Insider Trading History at Cencora

Paul E. Szurek Buying and Selling Activity at Cencora

Cencora Company Overview

Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Today's Range

Now: $241.64

$241.43

$242.97

50 Day Range

MA: $232.96

$219.50

$249.95

2 Week Range

Now: $241.64

$195.83

$251.56

Volume

23,272 shs

Average Volume

1,397,708 shs

Market Capitalization

$47.62 billion

P/E Ratio

32.18

Dividend Yield

0.91%

Beta

0.44